Skip to main content
Premium Trial:

Request an Annual Quote

Altona, German Institute Co-developing Tests for Tropical Diseases

NEW YORK (GenomeWeb News) – Germany's Bernhard Nocht Institute for Tropical Medicine and ADT Altona Diagnostic Technologies recently announced a collaboration to develop and market tests for tropical diseases.

The public-private partnership is budgeted for €9.6 million ($12.6 million) over the next four years, with €4.6 million in funding provided by the government of the City of Hamburg in Germany. The money is from the European Fund of Regional Development, an instrument of the European Union.

A "core element" of the partnership will be a specimen bank dedicated to several tropical and rare diseases, though the institute and Altona did not elaborate. In addition to being used by the partners for test development, the reference specimens will be accessible to third parties and customers, they said.

Both the institute and Altona are based in Hamburg. The institute focuses on serologic test development and has expertise in the epidemiology of tropical diseases. It also has a collection of tropical and orphan pathogens and specimens from infected patients.

Altona develops nucleic acid-based tests with a focus on infectious diseases.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.